New range of recombinant Fab monoclonal antibodies launched by BBI Solutions at Medica 2013

BBI Solutions, a world leader in immunoassay development and contract manufacturing, recently launched its unique range of Recombinant Fab Monoclonal Antibodies at the American Association for Clinical Chemistry’s (AACC) Annual Meeting and Clinical Lab Expo, on July 28-August 31, 2013, in Houston, Texas.

Developed and screened using Phage Display and Luminex technologies, each Recombinant Fab Monoclonal Antibody pair is selected from 1 billion antibody clones for affinity and sensitivity characteristics. The antibodies are now available to purchase from BBI Solutions. Dr James Steggles, Commercial Manager at BBI Solutions, comments on BBI Solutions’ range of Recombinant Fab Antibodies:

“Here at BBI Solutions it is our aim to ensure that we supply the market with antibodies that have world-class performance and give our customers significant advantages over their competitors. Each antibody pair is the best from a billion clones screened and 4500 matched pairs tested. By using this new range of monoclonal antibodies, they can produce clinical assays that are more sensitive and reliable than their competitors, as well as more cost-effective due to reduced R&D costs.”

James goes on to say:

“Antibodies are usually the key to a good disease diagnosis assay and the most important aspect of them is performance. It can take a lot of R&D time and spend to evaluate an antibody only to find it doesn’t quite meet your performance criteria.

Our antibody pairings are selected from 1 billion clones and their performance has been evaluated with specific clinical conditions in mind. For example, our anti-Calcitonin antibodies have been shown to detect Calcitonin at a dynamic range of 6 to 2000 picograms per mL, which is ideal for specific clinical conditions. The antibodies have extremely good affinity (picomolar) and sensitivity characteristics.”

The antibodies are produced in E. coli meaning production is much simpler than for antibodies developed using hybridoma cell culture. Therefore, production is much quicker and more reliable than standard cell culture techniques, and large scale production is not a problem.

The new Recombinant Fab Mouse Monoclonal Antibodies from BBI Solutions exhibit significant advantages over standard mouse monoclonal antibodies. From the screening process to testing in patient samples to ensure clinical significance, BBI Solutions’ methodology ensures that companies developing new assays have the most sensitive and reliable antibodies available in the market.

There are 32 biomarkers covered at the moment including CRP, Cystatin C, Calcitonin, Giardia lamblia, E. histolytica, ST2, S100 Beta and MPO, with more being developed.

To book an appointment with BBI Solutions at the MEDICA Tradeshow 2013 in Dusseldorf on the 20^th-23^rd November to discuss their new range of Recombinant Fab Monoclonal Antibodies, please visit the Medica 2013 page on the BBI Solutions site. Alternatively, please visit Hall1, Booth F24 to further discuss.